On December 15, 2021 Endomag reported that A novel procedure could now spare breast cancer patients an invasive surgical procedure on their lymphatic system (Press release, Endomag, DEC 15, 2021, View Source [SID1234597246]). At MD Anderson Cancer Center, doctors have pioneered the Targeted Axillary Dissection (TAD) technique, where a tiny magnetic seed is placed into patient lymph nodes known to contain cancer. Following a course of neoadjuvant chemotherapy aimed to shrink or even eradicate their cancer, prior to surgery, this novel technique allows surgeons to monitor the response of targeted lymph nodes to the chemotherapy without the need for upfront invasive surgery, such as a complete axillary dissection.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The magnetic seed, known as a Magseed allows surgeons to accurately remove the node marked prior to chemotherapy and remove it with minimal damage to healthy lymph node tissue.
Lymph nodes are a vital part of the system which helps the body to fight infection but are also the first structures breast cancer can spread to. In 40 to 75% of women, a course of chemotherapy before surgery can clear the nodes of cancer.1,2,3 However, until now, there has been no way to confirm the chemotherapy has been effective without removing a large number of lymph nodes from the underarm.
"The standard surgical approach for patients with breast cancer that has spread to the lymph nodes has been axillary lymphadenectomy (ALND), which involves removing most of the lymph nodes in the axilla," explains Dr Abigail Caudle, MD, who first pioneered the TAD technique at MD Anderson. "Unfortunately, this approach is associated with significant complications which can impact a patient’s quality of life including swelling, pain, and decreased range of motion. Some patients have an excellent response to chemotherapy and may have no disease remaining in the lymph nodes. We suspect that these patients may not benefit from having all of their lymph nodes removed, although the studies looking at this question are not yet available.
The challenge has been how to identify these patients that might benefit from less aggressive surgery. By specifically removing the exact lymph nodes that had confirmed cancer at the time of diagnosis, as well as the lymph nodes most likely to contain disease, we can now accurately assess whether there is cancer remaining in the lymph nodes and consider no further surgery if there is no evidence of cancer."
It is widely reported that up to 70% of women who have multiple nodes removed in an ALND procedure will develop complications linked to their treatment, such as the life-altering condition of lymphedema.4,5,6 Lymphedema is a condition where damage to the lymphatic system results in a build-up of lymphatic fluid in the body as a result of lymphadenectomy, causing lifelong symptoms of severe swelling, altered sensation, pain and limitations in range of motion.3. There are currently more than 10m people in the United States living with lymphedema,7 and for many patients, lymphedema is incurable.8
"There is a sea-change afoot in the treatment of breast cancer as patients become increasingly educated about the options available to prevent side effects of treatment. Foremost on this list are procedures and technologies that can prevent lymphedema—an incurable, debilitating, progressive and disfiguring swelling that can occur when the lymphatic system is damaged during surgery, radiation or chemotherapy. Women who win their battle against breast cancer routinely state that lymphedema can be worse than their cancer. Their cancer was cured. Their lymphedema is forever. In this modern world, every woman deserves the full benefits of our knowledge to mitigate onset of the life-long disease of lymphedema," explains William Repicci, LE&RN President & CEO
The Magseed marker, used by surgeons at MD Anderson, is the world’s most studied non-radioactive seed, with the technology available in over 40 countries around the world. Results from a series of past and ongoing multi-national studies 9,10 have demonstrated the ease and accuracy of marking positive lymph nodes with a Magseed marker with 100% success in surgical retrieval, negating the need for unnecessary node removal.
"This pioneering surgery exemplifies the importance of new technologies such as Magseed in moving breast cancer treatment forward." said Eric Mayes, CEO of Endomag. "These technologies have already helped over 200,000 patients globally access a better standard of cancer care. We’re committed to continually learning from physicians around the world and providing access to cutting-edge clinical applications that will make a difference to these patients for years to come.